Breaking News Instant updates and real-time market news.

NVS

Novartis

$89.46

0.91 (1.03%)

06:17
08/19/19
08/19
06:17
08/19/19
06:17

Novartis to respond to demand for data manipulation details, Reuters says

Novartis plans to answer U.S. Senate Finance Committee Chairman Chuck Grassley, who demanded details about data manipulation related to its gene therapy Zolgensma, amid scrutiny of the drugmaker's decision to delay informing regulators until after the treatment's approval, Reuters' John Miller reports. "We are planning to respond but we haven't submitted yet," a spokesman says. Reference Link

  • 19

    Sep

  • 25

    Sep

NVS Novartis
$89.46

0.91 (1.03%)

07/26/19
ADAM
07/26/19
NO CHANGE
Target $37
ADAM
Buy
Homology Medicines selloff yesterday a buying opportunity, says Canaccord
Canaccord Genuity analyst Michelle Gilson attributes the selloff yesterday in shares of Homology Medicines (FIXX) to a pre-printed, and not peer-reviewed, paper that did not support the company's in vitro data around HR-mediated gene editing. The paper's author, who has previously worked with Sangamo Therapeutics (SGMO) on ZFN-mediated editing, was unable to induce homologous recombination without a nuclease, Gilson tells investors in a research note. "It is tough to understand why an author would choose this route of publication for a study of this nature," says the analyst. She sees "several key differences" between the author's and Homology's in vitro experiments. Further, Homology's technology has been externally validated, allowing Novartis (NVS) and other labs to perform their own in-house experiments using Homology plasmids, Gilson contends. She adds that following this validation, Novartis entered into a collaboration specifically revolving around Homology's gene editing technology for ophthalmic targets. The analyst keeps a Buy rating on Homology Medicines with a $37 price target. Gilson views the selloff in the shares as a buying opportunity into the Phase 1/2 pheNIX data by the end of 2019 for HMI-102 gene therapy in phenylketonuria.
08/10/19
PIPR
08/10/19
NO CHANGE
Target $210
PIPR
Overweight
Amgen wins 'big' in courtroom, Enbrel overhang removed, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond reiterates an Overweight rating and a $210 price target on Amgen's (AMGN) shares following news that the company has won the Enbrel IP litigation with challenger Sandoz. The analyst notes that this challenge could have pulled forward Enbrel's LOE from 2029 to essentially right now, which has been the number 1 concern surrounding the stock. With shares up about 6% on this news, Raymond sees the reaction as appropriate and, while the stock is approaching his target at these levels, he believes shares are likely to grind higher on this removed overhang. Sandoz is a division of Novartis (NVS).
08/12/19
LEHM
08/12/19
NO CHANGE
Target $31
LEHM
Overweight
Coherus should be bought on weakness from Enbrel ruling, says Barclays
Barclays analyst Balaji Prasad recommends buying shares of Coherus Biosciences (CHRS) on any weakness from Amgen's (AMGN) favorable Enbrel patent ruling against Novartis (NVS). Coherus is developing its own Enbrel generic, says the analyst, whose model already factors a launch in Q2 of 2029, following the expiration of the last U.S. Enbrel patent. As such, Prasad is making no change to his estimates following Friday's decision. He remains positive on Coherus and would use any share weakness as an opportunity to add a "fundamentally sound company." Prasad reiterates an Overweight rating on the shares with a $31 price target.
08/13/19
OPCO
08/13/19
NO CHANGE
Target $230
OPCO
Outperform
Amgen price target raised to $230 from $210 at Oppenheimer
Oppenheimer analyst Jay Olson raised his price target for Amgen (AMGN) to $230 from $210 after the U.S. District Court determined that Sandoz has not met the burden to prove all seven asserted claims invalid and upheld several Enbrel patents. The analyst suspects Sandoz will appeal but views the outcome as highly favorable for Amgen and models flat Enbrel sales until 2021 before declining. Sandoz is a division of Novartis (NVS). Olson reiterates an Outperform rating on Amgen's shares.

TODAY'S FREE FLY STORIES

SMTX

SMTC Corp.

$2.96

0.16 (5.71%)

05:35
09/20/19
09/20
05:35
09/20/19
05:35
Conference/Events
SMTC Corp. to host conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 12

    Nov

ENLAY

Enel

$0.00

(0.00%)

05:32
09/20/19
09/20
05:32
09/20/19
05:32
Upgrade
Enel rating change  »

Enel upgraded to Buy from…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNV

Synovus

$36.17

-1.075 (-2.89%)

05:31
09/20/19
09/20
05:31
09/20/19
05:31
Downgrade
Synovus rating change  »

Synovus downgraded to In…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 13

    Nov

W

Wayfair

$128.67

-3.065 (-2.33%)

05:29
09/20/19
09/20
05:29
09/20/19
05:29
Initiation
Wayfair initiated  »

Wayfair initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XYL

Xylem

$77.99

-0.41 (-0.52%)

05:29
09/20/19
09/20
05:29
09/20/19
05:29
Initiation
Xylem initiated  »

Xylem initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 23

    Sep

  • 31

    Oct

PRDSY

Prada

$0.00

(0.00%)

05:28
09/20/19
09/20
05:28
09/20/19
05:28
Downgrade
Prada rating change  »

Prada downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BURBY

Burberry

$0.00

(0.00%)

05:27
09/20/19
09/20
05:27
09/20/19
05:27
Upgrade
Burberry rating change  »

Burberry upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JSAIY

J Sainsbury

$0.00

(0.00%)

05:26
09/20/19
09/20
05:26
09/20/19
05:26
Upgrade
J Sainsbury rating change  »

J Sainsbury upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FCX

Freeport McMoRan

$10.45

0.095 (0.92%)

05:25
09/20/19
09/20
05:25
09/20/19
05:25
Initiation
Freeport McMoRan initiated  »

Freeport McMoRan…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 25

    Sep

ANFGY

Antofagasta

$0.00

(0.00%)

05:23
09/20/19
09/20
05:23
09/20/19
05:23
Downgrade
Antofagasta rating change  »

Antofagasta downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ATRC

AtriCure

$26.02

0.22 (0.85%)

05:21
09/20/19
09/20
05:21
09/20/19
05:21
Recommendations
AtriCure analyst commentary  »

AtriCure one of the most…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

STIM

Neuronetics

$10.50

-0.54 (-4.89%)

05:19
09/20/19
09/20
05:19
09/20/19
05:19
Recommendations
Neuronetics analyst commentary  »

Piper calls Neuronetics a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FGEN

FibroGen

$39.69

-1.3 (-3.17%)

, ALPMY

Astellas Pharma

$0.00

(0.00%)

05:16
09/20/19
09/20
05:16
09/20/19
05:16
Hot Stocks
FibroGen, Astellas Pharma announce Japanese approval of Evrenzo »

FibroGen (FGEN) and…

FGEN

FibroGen

$39.69

-1.3 (-3.17%)

ALPMY

Astellas Pharma

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

VOPKY

Koninklijke Vopak

$0.00

(0.00%)

05:16
09/20/19
09/20
05:16
09/20/19
05:16
Upgrade
Koninklijke Vopak rating change  »

Koninklijke Vopak…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LBTYA

Liberty Global

$27.09

-0.25 (-0.91%)

05:12
09/20/19
09/20
05:12
09/20/19
05:12
Downgrade
Liberty Global rating change  »

Liberty Global downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 07

    Nov

HRI

Herc Holdings

$45.32

-1.615 (-3.44%)

, URI

United Rentals

$125.06

0.415 (0.33%)

05:06
09/20/19
09/20
05:06
09/20/19
05:06
Upgrade
Herc Holdings, United Rentals rating change  »

Herc Holdings upgraded to…

HRI

Herc Holdings

$45.32

-1.615 (-3.44%)

URI

United Rentals

$125.06

0.415 (0.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Oct

URI

United Rentals

$125.06

0.415 (0.33%)

05:03
09/20/19
09/20
05:03
09/20/19
05:03
Upgrade
United Rentals rating change  »

United Rentals upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Oct

SUZ

Suzano

$15.97

-0.43 (-2.62%)

04:59
09/20/19
09/20
04:59
09/20/19
04:59
Downgrade
Suzano rating change  »

Suzano downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ROKU

Roku

$133.76

3.97 (3.06%)

, CMCSA

Comcast

$46.68

-0.25 (-0.53%)

04:56
09/20/19
09/20
04:56
09/20/19
04:56
Initiation
Pivotal starts 'dramatically overvalued' Roku with Sell rating, $60 target »

Pivotal Research analyst…

ROKU

Roku

$133.76

3.97 (3.06%)

CMCSA

Comcast

$46.68

-0.25 (-0.53%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 27

    Oct

FTCH

Farfetch

$8.91

-0.42 (-4.50%)

04:55
09/20/19
09/20
04:55
09/20/19
04:55
Conference/Events
Cowen retail/luxury analyst to hold an analyst/industry conference call »

Retail & Luxury Goods…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

FB

Facebook

$190.15

1.96 (1.04%)

, SNAP

Snap

$16.87

-0.04 (-0.24%)

04:55
09/20/19
09/20
04:55
09/20/19
04:55
Conference/Events
FBN Securities Tech/Internet analyst to hold a group luncheon »

technology and Internet…

FB

Facebook

$190.15

1.96 (1.04%)

SNAP

Snap

$16.87

-0.04 (-0.24%)

TWTR

Twitter

$42.94

-0.29 (-0.67%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 24

    Sep

  • 27

    Oct

TRGP

Targa Resources

$40.89

-0.725 (-1.74%)

04:55
09/20/19
09/20
04:55
09/20/19
04:55
Conference/Events
Targa Resources management to meet with RBC Capital »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

IRM

Iron Mountain

$32.15

-0.02 (-0.06%)

04:55
09/20/19
09/20
04:55
09/20/19
04:55
Conference/Events
Iron Mountain management to meet with RBC Capital »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

LGND

Ligand

$104.62

5.37 (5.41%)

04:55
09/20/19
09/20
04:55
09/20/19
04:55
Conference/Events
Ligand management to meet with Craig-Hallum »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 02

    Oct

  • 13

    Nov

RDFN

Redfin

$17.19

-0.62 (-3.48%)

04:55
09/20/19
09/20
04:55
09/20/19
04:55
Conference/Events
Redfin management to meet with Wedbush »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.